<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2012</study_start_year><condition>PAZIENTI CON METASTASI EPATICHE COLORETTALI NON SUSCETTIBILI DI CHIRURGIA</condition><condition>Liver metastases</condition><condition>PATIENTS WITH LIVER COLORECTAL METASTASES NOT CANDIDATED TO SURGERY</condition><disease>Patients With Liver Colorectal Metastases Not Candidated To Surgery</disease><disease>Pazienti Con Metastasi Epatiche Colorettali Non Suscettibili Di Chirurgia</disease><disease>Liver Metastases</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2530668</full_dataset_link><location>Italy</location><study_start_month>4</study_start_month><keyword>ERBITUX*INFUS 1FL 50ML 5MG/ML</keyword><repository>ECRIN MDR</repository><study_status>Ongoing</study_status></additional><is_claimable>false</is_claimable><name>Tumour markers response to chemotherapy in patients with colorectal liver metastases</name><description>Primary objectives: COMPLETE LIVER RESECTION AFTER CHEMOTHERAPY
Primary endpoints: COMPLETE RESECTION OF LIVER METASTASES</description><dates><creation>2012-04-15</creation></dates><accession>2530668</accession><cross_references><EU Clinical Trials Register>2012-000834-21</EU Clinical Trials Register></cross_references></HashMap>